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Abstract 
 
Background: For critically ill adult patients with acute traumatic brain injury (TBI), we assessed the 
clinical and cost-effectiveness of:  
a) Management in dedicated neurocritical care units versus combined neuro/general critical care 
units within neuroscience centres. 
b) ‘Early’ transfer to a neuroscience centre versus ‘no or late’ transfer for those who present at a 
non-neuroscience centre. 
Methods: The Risk Adjustment In Neurocritical care (RAIN) Study included prospective admissions 
following acute TBI to 67 UK adult critical care units during 2009-11. Data were collected on baseline 
case-mix, mortality, resource use, and at six months, Glasgow Outcome Scale Extended (GOSE), and 
quality of life (QOL) (EuroQol 5D-3L). We report incremental effectiveness, costs and cost per 
Quality-Adjusted Life Year (QALY) of the alternative care locations, adjusting for baseline differences 
with validated risk prediction models. We tested the robustness of results in sensitivity analyses. 
Findings: Dedicated neurocritical care unit patients (N=1,324) had similar six-month mortality, 
higher QOL (mean gain 0.048, 95% CI -0.002 to 0.099) and increased average costs compared with 
those managed in combined neuro/general units (N=1,341), with a lifetime cost per QALY gained of 
£14,000. ‘Early’ transfer to a neuroscience centre (N=584) was associated with lower mortality (odds 
ratio 0.52, 0.34 to 0.80), higher QOL for survivors (mean gain 0.13, 0.032 to 0.225), but positive 
incremental costs (£15,001, £11,123 to £18,880) compared with ‘late or no transfer’ (N=263). The 
lifetime cost per QALY gained for ‘early’ transfer was £11,000.  
Conclusions: Within neuroscience centres, for critically ill adult patients with acute TBI, management 
in dedicated neurocritical care units is, on average, more cost-effective than in combined 
neuro/general units.   This study finds that ‘early’ transfer to a neuroscience centre is associated 
with reduced mortality, improvement in QOL and is cost-effective. 
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Introduction 
Acute traumatic brain injury (TBI) is a major cause of death, and disability.1 The annual cost of acute 
TBI has been estimated at $60 billion in the USA.2 For critically ill adult patients with acute TBI, 
access to specialist facilities, for example neuroscience centres, may differ across regions, but these 
variations are not informed by evidence of relative effectiveness or cost-effectiveness.3 Some 
evidence indicates that management of acute TBI in specialist neuroscience centres rather than non-
neuroscience centres, may be associated with improved clinical outcomes.4, 5 Several case series 
have suggested that dedicated clinical algorithms and protocols can improve mortality and 
functional outcomes following acute TBI,6, 7 but in the absence of RCTs, confounding is a key 
concern, and previous studies have not undertaken adequate risk-adjustment when comparing 
outcomes across settings,8 or considered relative costs. 
 
In the UK NHS, the majority of acute TBI patients admitted to neuroscience centres are managed in 
neurocritical care units rather than combined neuro/general critical care units. However, the recent 
expansion of neurocritical care facilities is based on weak evidence of benefit from managing severe 
head injury in specialist centres.5 It is also unknown whether adult TBI patients without an acute 
‘neurosurgical’ lesion benefit from ‘early’ transfer to a neuroscience centre; there may be a 
substantial risk of death from ‘early’ transfer and aggressive protocols of care in a neuroscience 
centre.9, 10 A competing concern, is that if the initial decision is not to transfer the patient to a 
neuroscience centre, critical lesions may develop subsequently; the patient may require a ‘late’ 
transfer at increased risk of an unfavourable outcome.11 While ‘early’ transfer to neuroscience 
centres has been recommended following acute TBI, the lack of evidence underpinning this guidance 
has been recognised by the National Institute for Health and Care Excellence (NICE), who listed this 
topic as a key area for further research.12 
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The Risk-Adjustment in Neurocritical Care (RAIN) Study aimed first, to validate risk prediction models 
following acute TBI in adult critical care units in the UK, and second to compare risk-adjusted 
outcomes and costs of alternative care locations following acute TBI.13  
 
The objectives of this paper are to use the RAIN Study data to compare the effectiveness, costs, and 
cost-effectiveness of:  
1. Management in a dedicated neurocritical care unit versus a combined neuro/general critical 
care unit; 
2. ‘Early’ transfer to a neuroscience centre versus ‘no or late’ transfer, for patients who initially 
present at a non-neuroscience centre and do not require urgent neurosurgery.  
 
Methods 
Overview  
This study compared the risk-adjusted outcomes, costs and lifetime cost-effectiveness of alternative 
care locations following acute TBI. Firstly, for patients admitted to neuroscience centres, we 
compared care within a dedicated neurocritical care unit (Figure 1a, panel A) versus within a 
combined neuro/general critical care unit (Figure 1a, panel B). Secondly, for patients who originally 
presented at a non-neuroscience centre, an ‘early’ transfer group was defined as those patients who 
transferred to a neuroscience centre, either directly from the emergency department, or from a 
critical care unit within 18 hours of initial hospital presentation (Figure 1b, panel A).  The ‘no or late’ 
transfer group were defined as patients who received all their critical care within a non-
neuroscience centre, and those who transferred to a neuroscience centre more than 24 hours after 
initial hospital presentation (Figure 1b, panel B). The cut-off times were chosen a priori by the 
clinical experts on the RAIN Study Steering Group. The definition of an ‘early’ transfer was intended 
to include all those patients where the initial decision was to transfer the patients, recognising local 
variations in the care pathway and logistical barriers to immediate transfer. Patients transferred 
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between 18 and 24 hours, and those who underwent neurosurgery for evacuation of a mass lesion 
within 24 hours of initial hospital presentation, were excluded. Within the ‘no or late’ transfer group, 
94% of patients were not transferred to a neuroscience centre.13 
 
Settings, patients and measurement of six month outcomes and costs  
The outcomes and costs of the alternative care locations were estimated from the RAIN Study.13 The 
RAIN Study recruited admissions following acute TBI to 67 adult critical care units in the UK during 
2009-11. Each critical care unit was classified according to whether or not it was within a 
neuroscience centre, and if so, whether it was within a dedicated neurocritical care unit, or a 
combined neuro/general critical care unit. Within UK neuroscience centres, the RAIN Study included: 
all 13 centres with dedicated neurocritical care units, 14 (82% of the total) with combined 
neuro/general units and four additional units that did not meet either definition. The RAIN Study 
also included patients from 36 (16%) general critical care units in non-neuroscience centres.  
All adult patients admitted to participating critical care units with a confirmed TBI and a last pre-
sedation Glasgow Coma Scale (GCS) of 3-14 were included. Detailed information was collected at the 
time of injury and at initial hospital presentation on age, sex, cause of injury, major extracranial 
injury, pupil reactivity, GCS, computed tomography (CT) characteristics (Marshall CT classification14). 
These baseline variables were used to predict the risks of death at six months according to the 
IMPACT Lab14 and CRASH CT15 risk prediction models. There two models were chosen following a 
review of published risk prediction models for critically ill adult patients with acute TBI,8, 16 and were 
those found to perform best in external validation undertaken in the RAIN Study.13  
 
Six month outcomes 
For the index admission, information on vital status and the date of death were recorded on the 
RAIN Study Case Report Forms (CRFs). RAIN Study data were linked with death registration from the 
NHS information centre to give survival status and date of death for patients discharged from the 
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initial hospital episode. At the six month follow-up, a postal questionnaire was administered to those 
patients known to be alive and eligible for follow-up.13 Patients (or their carers) were asked to 
complete the Glasgow Outcome Scale (Extended) (GOSE), and a generic health-related quality of life 
(QOL) questionnaire, the EuroQol 5-dimension, 3-level version (EQ-5D-3L). Unfavourable outcome at 
six months was measured as death or severe disability according to the GOSE.17 The EQ-5D-3L 
profiles were combined with health state preference values from the UK general population,18 to 
give EQ-5D-3L utility index scores on a scale anchored at 0 (death) and 1 (perfect health). Quality-
Adjusted Life Years (QALYs) were then reported by combining data on vital status and utility score at 
six months.  Decedents were assigned zero QALYs.  
 
Resource use and costs 
The cost analysis took a health and personal social services perspective. The RAIN CRFs recorded 
length of stay (LOS) in critical care units and general medical wards from index admission and 
readmission. The CRFs also recorded whether or not the patient had intracranial neurosurgery for 
evacuation of a mass lesion.  Each critical care bed-day was assigned to the appropriate Healthcare 
Resource Group (HRG) with daily organ support data recorded for the Critical Care Minimum Dataset 
(CCMDS).19 Data on other health and personal social service use (between discharge from the index 
hospital admission and six months follow-up) was collected from a service use questionnaire 
administered by post at the six month follow-up. 13 Unit costs for resource use were taken from the 
‘Payment by Results’ database20 and the literature (see Web supplement, Table S1). All unit costs 
were reported in 2010-11 prices.  
 
Analysis of six month costs and consequences 
Regression analysis used the IMPACT Lab model14 which performed best in external validation in the 
RAIN Study. For mortality and unfavourable outcome at six months after the acute TBI, odds ratios 
were reported with logistic regression. For the comparisons of QOL, QALYs and cost at six months, 
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we reported mean differences after adjustment with linear regression. For the first comparison we 
allowed for any clustering of patients within critical care units with multilevel models. For the second 
comparison, patients within each critical care unit could be in either comparison arm, we used 
single-level regression models for case-mix adjustment and to report pre-specified subgroup 
analyses according to age (70 years or less, or over 70 years), major extracranial injury (yes or no) 
and severity of TBI (GCS of 9-14, or 3-8).21 Missing data were addressed with multiple imputation  
assuming that data were ‘missing at random’,22 that is conditional on baseline covariates, resource 
use, and observed endpoints. We applied the analytical models to each imputed dataset (n=25), and 
combined the resultant estimates with Rubin’s rules.22 
 
Lifetime cost-effectiveness analysis 
We predicted patient-level lifetime costs and QALYs which required assumptions to be made about 
long-term survival, QOL and cost (see Web supplement for details, including Figures S1 and S2, and 
Tables S2-S4). We reported lifetime incremental costs, QALYs, and incremental cost-effectiveness 
ratios (ICERs). Incremental net monetary benefits (INBs) were estimated by valuing incremental 
QALYs at £20,000 per QALY, and subtracting from this the incremental costs.  Cost-effectiveness 
acceptability curves (CEACs) were calculated by reporting the probability that each alternative was 
the most cost-effective (i.e. had a positive INB) at different ceiling ratios of willingness to pay for a 
QALY gain. Lifetime costs and QALYs were discounted at 3.5%. We undertook sensitivity analyses to 
assess whether the cost-effectiveness results were robust to alternative assumptions. The base case 
assumptions and sensitivity analyses undertaken were as follows:   
(a) In the base case analysis, for those surviving six months after hospital presentation, subsequent 
death rates were assumed to be the the same as for the age-gender matched general 
population.13, 23 In this sensitivity analysis, lifetime mortality was estimated by applying the 
parametric function judged the most plausible (Gompertz) to the observed data.24 
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(b) The base case assumed that QOL at 10 years post acute TBI was 5% lower than for the age-
gender matched general population.25 In the sensitivity analysis, we instead assumed that the 
decrement in QOL reported in the RAIN Study at six months versus the general population, was 
maintained over the patients’ lifetime.  
(c) The costs considered from six months after the acute TBI were those from readmissions to 
general medical wards, and from use of outpatient and community services. In the base case 
analysis these costs were applied for three years, after which no further costs were assumed to 
be attributable to the acute TBI. The sensitivity analyses considered (i) readmission costs to 
general medical wards for five years; and (ii) outpatient and community costs for upto 10 years. 
(d) In the base case analysis, the unit costs of critical care were allowed to differ across clinical 
centres, according to the variations observed in the Payment by Results database. In the 
sensitivity analysis, the same unit costs were assumed across care locations. 
(e) The base case analysis assumed QOL data from the RAIN Study applied to the six month time-
point, irrespective of the time at which the QOL questionnaire was completed. In the sensitivity 
analysis, we assumed that patients whose follow-up was before 150 or after 220 days, had 
missing QOL data, and used multiple imputation to impute their six month QOL data. 
(f) We assumed that costs followed a Normal distribution in the base case analysis, whereas the 
sensitivity aanalysis assumed they followed a Gamma distribution. 
(g) Risk equations from the IMPACT LAB model were applied in the base case analysis, and from the 
CRASH CT model15 in the sensitivity analysis. 
(h) ‘Early’ transfer to a neuroscience centre was defined as within 18 hours of hospital presentation 
in the base case and within eight hours of hospital presentation in the sensitivity analysis. 
(i) In the base case, the second comparison included all patients irrespective of their pupil 
reactivity. In the sensitivity analysis, patients with neither pupil reactive were excluded. 
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Results 
Baseline characteristics 
For the patients with acute TBI admitted directly to neuroscience centres, baseline characteristics 
were similar between those admitted to dedicated neurocritical care units, versus combined 
neuro/general critical care units (Table 1).  For patients admitted to non-neuroscience centres the 
‘early’ transfer group were on average younger and less severely ill than the ‘no or late’ transfer 
group. The ‘no or late’ transfer group had a higher proportion of patients with a GCS of 3-8, 
unreactive pupils, and a Marshall CT classification indicating non-evacuated mass lesion.  The 
median predicted risk of death at six months was higher for the ‘no or late’ transfer group compared 
with the ‘early’ transfer group.  
 
Six month outcomes  
The proportion of patients who died before six months was similar following care in a dedicated 
neurocritical care unit versus those in a combined neuro/general critical care unit (Table 2a). The 
dedicated neurocritical care unit group had a higher mean EQ-5D-3L utility index score for survivors, 
a lower proportion of patients with unfavourable outcomes and higher mean QALYs, but none of 
these differences was statistically significant, after case-mix adjustment. A lower proportion of 
patients died before six months in the ‘early’ versus the ‘no or late’ transfer group (adjusted odds 
ratio 0.52, 95% CI 0.34 to 0.80; Table 2b).  The ‘early’ transfer group reported higher mean EQ-5D-3L 
utility index score for survivors, and higher average QALYs.  
 
The subgroup of patients aged over 70 (n=86) had a higher odds of death in the ‘early’ versus the ‘no 
or late’ transfer group, but the CIs around the odds ratio were wide and included 1 (Web 
supplement Table S5).  For the other subgroups, a higher proportion of patients died in the ‘no or 
late’ versus the ‘early’ transfer group. 
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Resource use and cost up to six months 
The dedicated neurocritical care unit group had a higher average LOS in critical care than the 
combined neuro/general critical care unit group, (Table 3a), which led to positive incremental costs 
at six months of approximately £3,700. For the ‘early’ transfer group the average LOS in critical care, 
on general wards and in total, was approximately double that of the ‘no or late’ transfer group 
(Table 3b).  A higher proportion of patients in the ‘early’ transfer group had an intracranial 
procedure for evacuation of a mass lesion, at least 24 hours after initial presentation. The ‘early’ 
transfer group, had a positive incremental cost overall (£15,000), and for each subgroup (Web 
supplement, Table S5). 
 
Lifetime CEA 
Critically ill adult patients with acute TBI admitted to neuroscience centres and managed in 
dedicated neurocritical care units rather than combined neuro/general critical care units, had higher 
average lifetime QALYs, at a small additional mean cost; the ICER was around £14,000 per QALY 
(Table 4a).  At a ceiling ratio of £20,000 per QALY, the INB was positive (£1,300).  The probability that 
dedicated versus combined neurocritical care units are cost-effective, is around 60% at realistic 
threshold willingness to pay for a QALY gain (Web supplement Figure S3a).  
For the patients admitted to non-neuroscience centres following acute TBI, the average lifetime 
QALYs and costs were both higher for the ‘early’ transfer group than the ‘no or late’ transfer group. 
The ICER was approximately £11,000 per QALY (Table 4b).  The corresponding probability that ‘early 
transfer’ to a neuroscience centre is cost-effective is almost 100% (Web supplement Figure S3b). 
 
The sensitivity analyses find that the base case findings are robust to most alternative approaches 
taken (Figure 2a and b). The exception is that if the second comparison excludes patients with 
neither pupil reactive, the effect of early transfer on six month mortality is reduced (adjusted odds 
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ratio 0.856, 95% CI 0.518 to 1.416), and the corresponding INB for ‘early’ transfer is negative with a 
95% CI that includes zero (Figure 2b).  
 
The subgroup analysis reported that ‘early’ transfer was highly cost-effective for patients aged 70 or 
less (n=761), but was not cost-effective for those aged over 70 (n=86), (Web supplement Figure S4a). 
For all other subgroups, ‘early’ transfer was more cost effective than ‘no or late’ transfer (Web 
supplement Figures S4b and S4c). 
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Discussion 
This paper finds that for critically ill patients with acute TBI who present at a neuroscience centre, 
average QOL after six months is higher following care in dedicated neurocritical care units than 
combined neuro/general units. However, this difference is not statistically significant and dedicated 
critical care units have higher critical care costs. For critically ill adult patients who present at a non-
neuroscience centre and do not require immediate neurosurgery following acute TBI, ‘early’ transfer 
to a neuroscience centre is associated with lower mortality after six months, and survivors have 
higher average QOL. The ‘early’ transfer group also has higher average total costs which reflect the 
increased survival, but the lifetime QALY gains are sufficient to justify the additional costs, and so 
‘early’ transfer is cost-effective.  This finding applies to all subgroups apart from for older patients 
(aged over 70). While the sensitivity analysis reports the results are generally robust to alternative 
assumptions, it does report that the ‘early transfer’ policy is no longer more effective or cost-
effective once patients with neither pupil reactive are excluded.  The ‘late or no’ transfer group had 
a higher proportion of patients with neither pupil reactive, and may therefore include a higher 
proportion of patients with unmeasured characteristics associated with increased mortality. Hence, 
any recommendation that critically ill patients with acute TBI should be transferred ‘early’ to 
neuroscience centres, has to recognise the potential for unobserved confounding.  
 
This paper extends the previous literature on the relative effectiveness of alternative locations of 
neurocritical care.26-28 This paper is the first to evaluate the cost-effectiveness of alternative care 
locations following acute TBI, and uses established risk prediction models, subject to a rigorous 
validation study in critically-ill adults with acute TBI. The finding that average risk-adjusted QOL is 
higher if acute TBI patients are managed in dedicated neurocritical care units, rather than a 
combined neuro/general critical care unit has several possible explanations.  First, a dedicated 
multidisciplinary team may provide more effective, immediate acute rehabilitation, and improve 
access to specialised neuro rehabilitation after discharge from the critical care unit.29 Second, 
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dedicated units may offer more aggressive monitoring and management, which can reduce 
morbidity,5 and the RAIN Study finds this did not increase six-month mortality.  Third, the dedicated 
neurocritical care units may have less severe case-mix according to unmeasured variables. Finally, 
the difference in the mean QOL between the settings may simply reflect chance variation as the 
differences was not statistically significant. 
 
The finding that ‘early’ transfer to a neuroscience centre following acute TBI patients is cost-
effective is driven by the gains in survival and QOL observed at six months after hospital 
presentation.  For non-surgical patients, previous research suggested that early transfer and more 
aggressive management may lead to increased risks that outweigh any gains,30 whereas other 
studies report that delayed transfer may lead to worse outcomes.11 In the RAIN Study, only a small 
proportion (6%) of the ‘no or late’ transfer group had a delayed transfer, and so the main contrast is 
between a decision to transfer the TBI patient to a neuroscience centre ‘early’, versus continued 
management at a non-neuroscience centre. Previous evidence suggests benefits from early transfer 
for patients presenting with a space occupying haematoma with worsening mass effect, but the 
RAIN Study excludes patients who required neurosurgery within 24 hours, and therefore extends the 
evidence on the effectiveness of early transfer, to other critically ill patients with TBI.  Here, while 
around one third of patients in both comparison groups presented with a mass lesion, only one 
patient in the ‘no or late’ transfer group had neurosurgery after 24 hours, compared to 48(8%) of 
patients in the ‘early’ transfer group.  
 
The definition of an ‘early’ transfer is arbitrary, and may differ across contexts.  A potential concern 
is that the effectiveness of an ‘early’ transfer policy could be highly sensitive to the cut-off point, and 
previous evidence from trauma networks encourages a four hour time window for neurosurgical 
interventions.3 Our sensitivity analysis suggests that applying an eight rather than an 18 hour time 
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window from hospital presentation does not have large impact on the effectiveness or the cost-
effectiveness of the ‘early’ transfer policy. 
 
This study has some limitations.  First, the RAIN Study only measured costs and outcomes for up to 
six months. The lifetime CEA made assumptions when extrapolating from these data, but the 
sensitivity analyses suggested the results were robust to alternative extrapolation methods. Second, 
some follow-up data were missing for the six month endpoints, which we addressed with multiple 
imputation approaches. Third, in any non-randomised comparison the major concern is residual 
confounding.  We allowed for baseline differences between the comparison arms with the published 
risk prediction model that performed best in external validation,14 and the sensitivity analysis 
suggested the results were similar when an alternative risk adjustment method was used. However, 
the results could be explained by differences between the comparison groups in prognostic factors 
that were not in the published risk models, nor measured in the RAIN Study.  For example, in the 
RAIN Study the definition of major extracranial injury was broad and did not recognise the injury’s 
severity. Further research would ideally record and adjust for potential confounders beyond those 
measured in the RAIN Study.  
 
Conclusions 
This paper finds that for critically ill adult patients with acute TBI who present at, or are transferred 
to, a neuroscience centre, management in a dedicated neurocritical care unit rather than a 
combined neuro/general critical care unit is associated with small gains in average QOL, at low 
additional costs, although these differences were not statistically significant. For adult patients with 
acute TBI who present at a non-neuroscience centre and do not require neurosurgery within 24 
hours, ‘early’ transfer is more cost-effective than ‘no or late’ transfer to a neuroscience centre, after 
risk adjustment.   
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Figure Legends 
 
Figure 1(a). Comparators for research objective 1: alternative care locations within neuroscience 
centres 
Figure 1(b). Comparators for research objective 2: ‘early’ versus ‘no or late’ transfer to a 
neuroscience centre  
Figure 2(a). Sensitivity analyses reporting mean (95% confidence intervals) incremental net 
monetary benefit (INB) comparing care for dedicated neurocritical care units versus combined 
neuro and general critical care units 
Figure 2(b). Sensitivity analyses reporting mean (95% confidence intervals) incremental net 
monetary benefit (INB) comparing ‘early’ versus ‘no or late’ transfer to a neuroscience centre 
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Table 1. Description of baseline characteristics 
 Comparison 1 Comparison 2 
 
 
Combined 
neuro and 
general  
critical care unit 
Dedicated  
neurocritical 
care unit 
‘No or late’ 
transfer to 
neuroscience 
centre 
‘Early’ transfer  
to neuroscience 
centre 
Number of admissions 1341 1324 263 584 
Age     
Mean (SD) 44.4 (18.8) 43.9 (18.7) 50.7 (20.1) 40.0 (17.4) 
Median (IQR) 43 (28, 58) 43 (26, 59) 49 (35, 69) 39 (24, 53) 
Male, n (%) 1023 (76.3) 1002 (75.7) 207 (78.7) 455 (77.9) 
Major extracranial injury, n (%) 590 (44.0) 488 (36.9) 110 (41.8) 209 (35.8) 
Pre-hospital hypoxiaa, %b 13.4 11.5 15.0 13.5 
Pre-hospital hypotensiona, %b 8.1 4.8 9.7 5.2 
Causes of TBI, n (%)     
Assault 136 (10.14) 180 (13.60) 29 (11.03) 94 (16.10) 
Fall 624 (46.53) 601 (45.39) 151 (57.41) 253 (43.32) 
Road traffic accidents 469 (34.97) 423 (31.95) 65 (24.71) 192 (32.88) 
Other 47 (3.50) 44 (3.32) 6 (2.28) 12 (2.05) 
Unknown 65 (4.85) 76 (5.74) 12 (4.56) 33 (5.65) 
Last pre-sedation GCS, n (%)     
13-14 (Mild TBI) 166 (12.4) 232 (17.5) 41 (15.6) 105 (18.0) 
9-12 (Moderate TBI) 352 (26.2) 340 (25.7) 62 (23.6) 173 (29.6) 
3-8 (Severe TBI) 823 (61.4) 752 (56.8) 160 (60.8) 306 (52.4) 
GCS motor score, %b     
6 (Obeys) 15.9 19.8 14.1 20.8 
5 (Localises) 32.2 30.8 26.5 35.4 
4 (Normal flexion) 12.3 12.0 10.3 11.2 
3 (Abnormal flexion) 8.1 6.9 4.9 4.9 
2 (Extension) 8.3 6.7 7.3 5.9 
1 (None) 23.2 23.7 36.7 21.8 
Pupil reactivityc, %b     
Both reactive 79.8 80.9 77.0 83.8 
One reactive 6.4 6.8 1.4 6.1 
Neither reactive 13.8 12.3 21.6 10.0 
Marshall CT classificationd, %b     
1 (Diffuse injury I) 2.7 4.3 10.9 2.4 
2 (Diffuse injury II) 35.0 30.4 45.6 42.4 
3 (Diffuse injury III) 8.4 9.6 8.4 16.7 
4 (Diffuse injury IV) 2.5 3.3 2.7 4.3 
5 (Evacuated mass lesion) 37.3 39.3 0.6 9.6 
6 (Non-evacuated mass lesion > 25ml) 14.1 13.1 31.8 24.6 
Traumatic subarachnoid haemorrhaged, %b 57.1 56.6 47.1 60.3 
Extradural haematomad, %b 16.7 17.5 9.6 14.8 
Predicted risk (%) at six months, median (IQR)b     
Death (IMPACT Lab model) 22.8 (11.5, 39.6) 22.5  (11.3, 36.9) 24.6 (9.6, 48.1) 18.3 (9.4, 32.7) 
Unfavourable outcome (IMPACT Lab model) 41.0 (22.9, 64.2) 40.0 (21.1, 60.7) 47.8 (20.8, 73.6) 33.8 (17.7, 54.3) 
Unfavourable outcome (CRASH CT model) 44.2 (24.3, 72.2) 42.5 (22.4, 70.3) 56.4(21.8, 83.1) 35.6 (19.1, 58.4) 
IQR: interquartile range; SD: standard deviation, GCS: Glasgow comma scale 
a Observed (hypoxia, SaO2<90%; hypotension, systolic blood pressure < 90 mmHg) or strongly suspected.  
b Summaries presented are after multiple imputation; number (%) missing each field were: hypoxia 171 (6.4); 
hypotension 179 (6.7); motor score 65 (2.4); pupil reactivity 198 (7.4); Marshall CT classification 189 (7.1); 
traumatic subarachnoid haemorrhage 175 (6.6); extradural haematoma 156 (5.9). 
c First recorded values after hospital presentation or, if unavailable, last recorded values pre-hospital. 
d From first CT scan following presentation at hospital. 
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Table 2. Mortality, EuroQol 5-dimension (EQ-5D), unfavourable outcome and quality-adjusted life years 
(QALY) at six months following acute TBI 
(a) Comparison 1: dedicated neurocritical care unit versus combined neuro and general critical care unit* 
 Combined neuro 
and general critical 
care unit 
(n=1,341) ‡* 
Dedicated 
neurocritical care 
unit 
(n=1,324) ‡* 
Incremental effect*** 
Mean [95% CI] 
Unadjusted Adjusted 
Death 341  
(25%) 
312  
(24%) 
0.982 
[0.950 to 1.020] 
0.942  
[0.768 to 1.155] 
 
Mean (SD) EQ-5D¥ 0.43  
(0.41) 
0.48  
(0.41) 
0.049 
[-0.001 to 0.098] 
0.048  
[-0.002 to 0.099] 
 
Unfavourable outcome† 841  
(63%) 
793  
(60%) 
0.888 
[0.690 to 1.150] 
0.902  
[0.739 to 1.099] 
 
Mean (SD) QALY 0.16  
(0.20) 
0.18  
(0.21) 
0.023 
[0.002 to 0.043] 
0.020  
[-0.001 to 0.040] 
 
 
(b) Comparison 2: ‘Early’ versus ‘no or late’ transfer to a neuroscience centre** 
 ‘No or late’ 
transfer to 
neuroscience 
centre 
(n=263) ‡** 
‘Early’ transfer to 
neuroscience 
centre 
 
(n=584) ‡** 
Incremental effect 
Mean [95% CI] 
Unadjusted Adjusted 
Death 107  
(41%) 
109  
(19%) 
0.334 
[0.242 to 0.462] 
0.521  
[0.338, 0.803] 
 
Mean (SD) EQ-5D¥ 0.44  
(0.37) 
0.55  
(0.41) 
0.108 
[0.011 to 0.205] 
0.129  
[0.032, 0.225] 
 
Unfavourable outcome† 169  
(65%) 
307  
(53%) 
0.609 
[0.173 to 2.150] 
0.884  
[0.280, 2.787] 
 
Mean (SD) QALY 0.13  
(0.18) 
0.22  
(0.21) 
0.093 
[0.056 to 0.130] 
0.051  
[0.015, 0.086] 
GOSE: Glasgow Outcome Scale (Extended); CI: confidence interval; SD: standard deviation 
*The response rates to six month questionnaires were similar across comparison groups. Response rate for 
GOSE and EQ-5D (3 level version) questionnaire in comparison 1 were 80% (77% in combined arm versus 
82% in dedicated arm) & 50% (49% in combined arm versus 52% in dedicated arm) respectively.  
**Response rate for GOSE and EQ-5D (3 level version) questionnaire in comparison 2 were 79% (75% in ‘no or 
late transfer’ arm versus 80% in early transfer arm) and 50% (46% in ‘no or late transfer’ arm versus 51% in 
‘early transfer’ arm) respectively.  
*** Odds ratio for death and unfavourable outcome; incremental for other estimates.  
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‡ Results reported as n (%) if not stated otherwise 
¥ Results reported for survivors 
† Death or severe disability 
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Table 3. Hospital resource use and costs (£) up to six months after acute TBI 
(a) Comparison 1: dedicated neurocritical care unit versus combined neuro and general critical care unit 
 Combined neuro and 
general  
critical care unit‡ 
(n=1,341) 
Dedicated 
neurocritical  
care unit‡ 
(n=1,324) 
Incremental cost* 
Mean [95% CI] 
(a1) Resource use    
Index admissiona    
Days in critical care 11.08 (10.83) 13.19 (15.07)  
Days on general medical wards 26.26 (36.03) 24.69 (33.96)  
Total hospital days – index admission 37.34 (40.49) 37.89 (39.62)  
Neuro-surgery**, n (%) 477 (35.57) 478 (36.10)  
n (%) readmission 66 (4.92) 100 (7.55)  
Total hospital days -readmissiona,b 0.68 (5.24) 0.80 (5.05)  
Total hospital days up to six monthsa,b 38.02 (41.27) 38.69 (40.49)  
 
(a2) Costs 
   
Index admissiona    
Critical care costs 16,685 (15,355) 20,274 (21,773)  
General medical costs 6,631 (9,122) 6,233 (8,592)  
Readmission costsa,b 1,374(4,970) 1,566(4,869)  
Outpatient & community costsb 777(1,939) 782(1,932)  
Total costs up to six monthsa,b 25,466 (21,468) 28,855 (25,970) 3,694 [1,899 to 5,489] 
 
 
(b) Comparison 2: ‘early’ versus ‘no or late’ transfer to a neuroscience centre 
 ‘No or late’ transfer to 
neuroscience centre  
 
(n=263) 
‘Early’ transfer  
to neuroscience 
centre  
(n=584) 
Incremental cost* 
Mean [95% CI] 
(b1) Resource use    
Index admissiona    
Days in critical care 5.67 (6.66) 13.93 (15.68)  
Days on general medical wards 12.73 (23.94) 24.31 (34.09)  
Total hospital days – index admission 18.40 (26.98) 38.24 (40.37)  
Neuro-surgery**, n (%) 1 (0.38) 48 (8.22)  
n (%) readmission 9 (3.42) 38 (6.51)  
Total hospital days -readmissiona,b 0.31 (2.24) 0.69 (3.98)  
Total hospital days up to six monthsa,b 18.71 (27.02) 38.94 (40.86)  
 
(b2) Costs 
   
Index admissiona    
Critical care costs 8,347(10,002) 19,632(22,922)  
General medical costs 3,209(6,022) 6,127(8,582)  
Readmission costsa,b 1,019(3,800) 1,589(5,077)  
Outpatient & community costsb 578(1,780) 1,178(2,700)  
Total costs up to six monthsa,b 13,153 (14,563) 28,525 (27,100) 15,001 [11,123 to 18,880] 
‡ Results reported as Mean(SD) unless stated otherwise 
*After case mix adjustment 
**Intracranial procedure for evacuation of mass lesion 
Source: a RAIN Study and CMP Database; b Health Services Questionnaire 
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CI: confidence interval; SD: standard deviation 
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Table 4. Lifetime costs (£), quality-adjusted life years (QALYs), and incremental net monetary benefit 
(INB) 
(a) Comparison 1: dedicated neurocritical care unit versus combined neuro and general critical care unit 
 
 
Combined neuro & 
general critical care unit 
(n=1,341) 
Dedicated neurocritical  
care unit 
(n=1,324) 
Incremental effecta 
Mean [95% CI] 
Mean (SD) Lifetime costs 31,007 (22,471) 34,909 (26,834) 3,167 [-464 to 6,797] 
Mean (SD) Lifetime QALYs 9.49 (6.52) 9.99 (6.56) 0.224 [-0.332 to 0.780] 
Lifetime cost per QALY   14,128  
INBb   1,316 [-9,857 to 12,489] 
  
 
(b) Comparison 2: ‘early’ versus ‘no or late’ transfer to a neuroscience centre 
 ‘No or late’ transfer to 
neuroscience centre 
 (n=263) 
‘Early’ transfer to 
neuroscience centre 
 (n=584) 
Incremental effecta 
Mean [95% CI] 
Mean (SD) Lifetime Costs 16,105 (15,041) 36,422 (28,030) 19,209 [15,234 to 23,184] 
Mean (SD) Lifetime QALYs 7.19 (6.88) 11.55 (6.43) 1.795 [1.049, 2.541] 
Lifetime cost per QALY   10,704  
INBb   16,682 [2,574 to 30,791] 
CI: confidence interval; SD: standard deviation 
a Incremental effects are after case-mix adjustment  
b INB can be calculated by following methods guidance and multiplying the mean QALY gain (or loss) by 
£20,000, and subtracting from this the incremental cost 
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FIGURES  
 
Figure 1(a).  
 
 
 
Figure 1(b).  
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Figure 2(a) 
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Figure 2(b) 
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Incremental  net benefits at £20,000 per QALY gain (early versus no/late transfer)
Vertical dashed line indicates incremental net benefits in the base case analysis. Solid vertical line indicates 
no difference in net monetary benefits between comparator groups.
(e) Followup between 150-270 days
(b) Quality of life weights from RAIN
(d) Same unit cost across location of care
(c1) Inpatient, outpatient &
community costs upto 5 years
Base case
(c2) Inpatient cost for 5 years, outpatient 
& community costs upto 10 years
(g) CRASH risk adjustment
(h) Early transfer 8 hours
(f) Gamma distributed costs
(a) Gompertz survival
(i) One or both pupil reactive
 
